Glaucoma News and Research

Latest Glaucoma News and Research

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges

A small subset of patients with open-angle glaucoma (OAG) account for a large proportion of all glaucoma-related charges in the United States, according to new data published by researchers at the University of Michigan Kellogg Eye Center and Washington University, St. Louis.

20 Sep 2012

Multiple interventions improve medication adherence for patients with chronic conditions

Although patients with chronic conditions who do not take medications as prescribed tend to have poorer health outcomes and higher health care costs than those who adhere to medication regimens, a new report sheds light on the potential for multiple interventions to improve medication adherence.

13 Sep 2012

Readily available index provides practical landmarks for glaucoma patients

The mean deviation index, a widely understood metric for summarizing damage to an individuals’ visual field, could help physicians estimate practical landmarks in patients with glaucoma such as fitness to drive, report UK researchers.

12 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis (PDP).

5 Sep 2012

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Singapore scientists have identified three new genes associated with Primary Angle Closure Glaucoma (PACG), a leading cause of blindness in Chinese people. PACG affects 15 million people worldwide, 80% of whom live in Asia.

5 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Johns Hopkins CIDR receives NIH contract to study genetic diseases

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

13 Aug 2012

Worldwide data reveal gaps in elderly eye care

Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.

10 Aug 2012

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Results of the highly anticipated Best Oral Presentation and Best Poster Awards were announced at SingHealth Duke-NUS Scientific Congress 2012, held on 3 and 4 August 2012 at the Raffles City Convention Centre.

8 Aug 2012

$Older Medicare patients have reduced risk of hip fracture following cataract surgery$

Older Medicare patients have reduced risk of hip fracture following cataract surgery

Medicare patients 65 years and older who underwent cataract surgery had a lower odds of hip fracture 1 year after the procedure when compared with patients with cataract who did not have cataract surgery, according to a study in the August 1 issue of JAMA.

1 Aug 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Glaucoma News and Research

Latest Glaucoma News and Research

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Small subset of patients with OAG accounts for large proportion of all glaucoma-related charges

Multiple interventions improve medication adherence for patients with chronic conditions

Readily available index provides practical landmarks for glaucoma patients

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Enrollment complete in ACADIA's pimavanserin Phase III trial for Parkinson's disease psychosis

Scientists identify three new genes associated with Primary Angle Closure Glaucoma

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Johns Hopkins CIDR receives NIH contract to study genetic diseases

Worldwide data reveal gaps in elderly eye care

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Older Medicare patients have reduced risk of hip fracture following cataract surgery

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Scientists discover new way to combat post-surgical scarring for glaucoma patients

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

AHAF announces glaucoma and macular degeneration research grants

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in